Masayuki Yanagisawa, H. Fujimaki, A. Takeda, M. Nemoto, Takayuki Sugimoto, Akio Sato
{"title":"非那雄胺对523名日本男性雄激素性脱发的长期疗效(10年)","authors":"Masayuki Yanagisawa, H. Fujimaki, A. Takeda, M. Nemoto, Takayuki Sugimoto, Akio Sato","doi":"10.15761/crt.1000273","DOIUrl":null,"url":null,"abstract":"Finasteride is a standard medical treatment for androgenetic alopecia; however, no long-term study of up to 10 years has been performed in Japan. Therefore, we evaluated the efficacy and safety of 1 mg/day finasteride in 532 Japanese men who were treated for androgenetic alopecia for 10 years. We performed subjective evaluations, using questionnaires administered to patients, in addition to the objective evaluation by doctors. The efficacy was assessed using the Norwood-Hamilton scale and modified global photographic assessment score, the standardized 7-point rating score using scalp photographs. For the Norwood-Hamilton classifications, stages IIa and IIv were combined as II, IIIa and IIIv were combined as III, IVa was combined as IV, and Va was combined as V. The proportions of patients with improvement (score ≥ 5) and prevention of disease progression (score ≥ 4) were 91.5% and 99.1%, respectively. The Norwood-Hamilton classification grading improved by approximately 1 grade from 3.35 ± 1.11 to 2.55 ± 1.30 after the 10-year treatment. The groups that showed Norwood-Hamilton: I/II/III and IV/V/VI/ VII at the first visit showed statistically significant differences in the modified global photographic assessment score at the 10-year treatment subjective evaluation (6.27 ± 0.62 vs 5.52 ± 0.78, P<0.001). Furthermore, the quantitative analysis of the objective evaluation using the questionnaire was also significantly different (P<0.001). During the study period, no serious adverse reaction was recognized. Long-term (10-year) treatment with 1 mg/day finasteride in Japanese men with androgenetic alopecia showed high efficacy in subjective and objective evaluations. *Correspondence to: Akio Sato, MD, PhD. Tokyo Memorial Clinic, 2F Yamaha Building, 2-16-7 Yoyogi, Shibuya-ku, Tokyo 151-0053, Japan, E-mail: drsato@ crux.ocn.ne.jp","PeriodicalId":90808,"journal":{"name":"Clinical research and trials","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":"{\"title\":\"Long-term (10-year) efficacy of finasteride in 523 Japanese men with androgenetic alopecia\",\"authors\":\"Masayuki Yanagisawa, H. Fujimaki, A. Takeda, M. Nemoto, Takayuki Sugimoto, Akio Sato\",\"doi\":\"10.15761/crt.1000273\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Finasteride is a standard medical treatment for androgenetic alopecia; however, no long-term study of up to 10 years has been performed in Japan. Therefore, we evaluated the efficacy and safety of 1 mg/day finasteride in 532 Japanese men who were treated for androgenetic alopecia for 10 years. We performed subjective evaluations, using questionnaires administered to patients, in addition to the objective evaluation by doctors. The efficacy was assessed using the Norwood-Hamilton scale and modified global photographic assessment score, the standardized 7-point rating score using scalp photographs. For the Norwood-Hamilton classifications, stages IIa and IIv were combined as II, IIIa and IIIv were combined as III, IVa was combined as IV, and Va was combined as V. The proportions of patients with improvement (score ≥ 5) and prevention of disease progression (score ≥ 4) were 91.5% and 99.1%, respectively. The Norwood-Hamilton classification grading improved by approximately 1 grade from 3.35 ± 1.11 to 2.55 ± 1.30 after the 10-year treatment. The groups that showed Norwood-Hamilton: I/II/III and IV/V/VI/ VII at the first visit showed statistically significant differences in the modified global photographic assessment score at the 10-year treatment subjective evaluation (6.27 ± 0.62 vs 5.52 ± 0.78, P<0.001). Furthermore, the quantitative analysis of the objective evaluation using the questionnaire was also significantly different (P<0.001). During the study period, no serious adverse reaction was recognized. Long-term (10-year) treatment with 1 mg/day finasteride in Japanese men with androgenetic alopecia showed high efficacy in subjective and objective evaluations. *Correspondence to: Akio Sato, MD, PhD. Tokyo Memorial Clinic, 2F Yamaha Building, 2-16-7 Yoyogi, Shibuya-ku, Tokyo 151-0053, Japan, E-mail: drsato@ crux.ocn.ne.jp\",\"PeriodicalId\":90808,\"journal\":{\"name\":\"Clinical research and trials\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical research and trials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15761/crt.1000273\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical research and trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/crt.1000273","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11
摘要
非那雄胺是治疗雄激素性脱发的标准药物;然而,在日本没有进行长达10年的长期研究。因此,我们评估了532名接受10年雄激素性脱发治疗的日本男性服用1mg /天非那雄胺的有效性和安全性。除了医生的客观评估外,我们还对患者进行了主观评估,使用问卷调查。采用诺伍德-汉密尔顿量表和改良的全球摄影评估评分(头皮照片的标准化7分评分)评估疗效。在Norwood-Hamilton分级中,IIa期和IIv期合并为II期,IIIa期和IIIv期合并为III期,IVa期合并为IV期,Va期合并为v期。改善(评分≥5分)和预防疾病进展(评分≥4分)的患者比例分别为91.5%和99.1%。治疗10年后,Norwood-Hamilton分级从3.35±1.11提高到2.55±1.30,提高了约1个等级。首次就诊时显示Norwood-Hamilton: I/II/III和IV/V/VI/ VII的组在10年治疗主观评价时的改良总体摄影评价评分差异有统计学意义(6.27±0.62 vs 5.52±0.78,P<0.001)。此外,使用问卷客观评价的定量分析也有显著差异(P<0.001)。在研究期间,未发现严重不良反应。长期(10年)服用1mg /天非那雄胺治疗日本男性雄激素性脱发在主观和客观评价中显示出很高的疗效。*通讯对象:佐藤昭夫,医学博士,博士。东京纪念诊所,日本东京都涉谷区代代木2-16-7号雅马哈大厦2楼,邮编:drsato@crux.ocn.ne.jp
Long-term (10-year) efficacy of finasteride in 523 Japanese men with androgenetic alopecia
Finasteride is a standard medical treatment for androgenetic alopecia; however, no long-term study of up to 10 years has been performed in Japan. Therefore, we evaluated the efficacy and safety of 1 mg/day finasteride in 532 Japanese men who were treated for androgenetic alopecia for 10 years. We performed subjective evaluations, using questionnaires administered to patients, in addition to the objective evaluation by doctors. The efficacy was assessed using the Norwood-Hamilton scale and modified global photographic assessment score, the standardized 7-point rating score using scalp photographs. For the Norwood-Hamilton classifications, stages IIa and IIv were combined as II, IIIa and IIIv were combined as III, IVa was combined as IV, and Va was combined as V. The proportions of patients with improvement (score ≥ 5) and prevention of disease progression (score ≥ 4) were 91.5% and 99.1%, respectively. The Norwood-Hamilton classification grading improved by approximately 1 grade from 3.35 ± 1.11 to 2.55 ± 1.30 after the 10-year treatment. The groups that showed Norwood-Hamilton: I/II/III and IV/V/VI/ VII at the first visit showed statistically significant differences in the modified global photographic assessment score at the 10-year treatment subjective evaluation (6.27 ± 0.62 vs 5.52 ± 0.78, P<0.001). Furthermore, the quantitative analysis of the objective evaluation using the questionnaire was also significantly different (P<0.001). During the study period, no serious adverse reaction was recognized. Long-term (10-year) treatment with 1 mg/day finasteride in Japanese men with androgenetic alopecia showed high efficacy in subjective and objective evaluations. *Correspondence to: Akio Sato, MD, PhD. Tokyo Memorial Clinic, 2F Yamaha Building, 2-16-7 Yoyogi, Shibuya-ku, Tokyo 151-0053, Japan, E-mail: drsato@ crux.ocn.ne.jp